Drugs / CRTE7A2-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06358053 | Apr 2024 → Dec 2027 expected | anal carcinoma, cervical cancer, head and neck cancer | Corregene Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRTE7A2-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06358053 ↗ |
| Modality | Cell therapy | “CRTE7A2-01 TCR-T cell therapy” NCT06358053 ↗ |